

References :

- **Adinolfi LE, Gambardella M, Andreana A, et al. (2001):** Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. *Hepatology*; 33:1358–1364.
- **Akuta N, Suzuki F, Sezaki H, et al.,(2006):** Predictive factors of virologic-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. *Journal of medical virology* 78:83-90
- **Alberti A, Morsica G, Chemello L, et al. (1992):** Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. *Lancet* ;340:697–698.
- **Alfaleh FZ, Hadad Q, Khuroo MS, et al. (2004):** Peginterferon alpha-2b plus 40. ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. *Liver Int*; 24(6):568-74.
- **Alter MJ (2007)** Epidemiology of hepatitis C virus infection. *World J Gastroenterol* 13: 2436–2441.
- **Amstrong G.L., Wasley A., Simard E.P., et al. (2006):** The prevalence of hepatitis C virus infection in the United States, 1999 through 2002, *Ann Int Med* 144, pp. 705–714.
- **Andrade, L. J.; Atta, A. M.; Junior, A. D.; et al. (2008):** Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin - A review. *Braz. J. Infect. Dis.*, 12 (2): S1413.

- **Armstrong GL (2003)** Commentary: modelling the epidemiology of hepatitis C and its complications. *Int J Epidemiol*; **32**: 725–26.
- **Asselah, T, Vidaud D, Doloy A, et al. (2003)**: Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy. *Gut*;52:900–902.
- **Authier FJ, Pawlotsky JM, Viard JP, et al. (1993)**: High incidence of hepatitis C virus infection in patients with cryoglobulinemic neuropathy. *Ann Neurol* ;34:749–750 (Abstract).
- **Backmund M, Meyer K, Von Zielonka M, Eichenlaub D (2001)**: Treatment of hepatitis C infection in injection drug users. *HEPATOLOGY*;34:188– 193.
- **Batts KP and Ludwig J (1995)**: Chronic hepatitis: an update on terminology and reporting. *Am J Surg Pathol* ;19:1409–1417.
- **Bedossa P, Poinard T, The French METAVIR Cooperative Study Group (1996)**: An algorithm for grading activity in chronic hepatitis C. *Hepatology* ;24:289–293.
- **Benhamou Y, Pockros P, Rodriguez-Torres M, et al. (2006)**: The safety and efficacy of virmidine plus pegylated interferon alfa-2B versus ribavirin plus pegylated interferon alfa-2B in therapy-naïve patients infected with HCV: phase 3 results. *J Hepatol* ;44:837-1012.
- **Berg T, Sarrazin C, Herrmann E. (2003)**: Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. *Hepatology*; 37(3): 600-609.
- **Bini EJ and Mehandru S. (2005)**: Sustained virological response rates and health-related quality of life after interferon and ribavirin

therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels. *Aliment Pharmacol Ther* 2005; 23:777–785.

- **Bressler BL, Guindi M, Tomlinson G et al. (2003):** High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. *Hepatology*; 38:639–644.
- **Bruno R, Sacchi P, Ciappina V, et al.(2004):** Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized,controlled study. *Antiviral Ther* ; 9(4): 491-497.
- **Bruno R, Sacchi P, Maiocchi L, et al.(2005):** Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naïve patients with chronic hepatitis C. *Antiviral Ther* ; 10(2): 201-205.
- **Bunn S, Kelly D, Murray KF, et al.(2000):** Safety, efficacy and pharmacokinetics of interferonalpha- 2b and ribavirin in children with chronic hepatitis C [Abstract]. *HEPATOLOGY*;32:350A.
- **Cacoub P, Carrat F, Bedossa P, et al.(2008):** Comparison of noninvasive liver fibrosis biomarkers in HIV/HCV co-infected patients: The fibrovic study - ANRS HC02. *J Hepatol*.
- **Cambridge, MA (2008):** Vertex Pharmaceuticals; June 9.Vertex reports 52% SVR12 rate for a 24-week telaprevir-based regimen in genotype 1 hepatitis C patients who failed prior treatment .

- **Camma C, Bruno S, Di Marco V et al.,(2006):** Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. *Hepatology* 2006 43(1):64-71.
- **Carey WD (2003) :** Tests and screening strategies for the diagnosis of hepatitis C. *Cleveland Clinic Journal*; 70:7-13.
- **Caruntu FA and Benea L (2006):** *Journal of Gastrointestinal and Liver Diseases* 15 (3): 249–56.
- **Centers for Disease Control and prevention (CDC) Viral Hepatitis (2001)** <http://www.cdc.gov/hepatitis/HCV/PDFs/HepCGeneralFactSheet.pdf>
- **Centers for Disease Control and prevention (CDC) Viral Hepatitis (2010) .** "Hepatitis C: FAQ | CDC Viral Hepatitis". Cdc.gov. Retrieved 2010-08-27.
- **Centers for Disease Control and prevention (CDC) Viral Hepatitis. (2008).** "Hepatitis C: FAQ – CDC Viral Hepatitis". Retrieved 13 June 2008.
- **Chan TM, Lok AS, Cheng IK, Ng IO (1993):** Chronic hepatitis C after renal transplantation. Treatment with alpha-interferon. *Transplantation*; 56:1095–1098.
- **Chang TT, Gish RG, de Man R, et al. (2006):** A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. *N Engl J Med* ;354:1001–1010.
- **Chen S.L. and Morgan T.R. (2006):** The natural history of hepatitis C virus (HCV) infection, *Int J Med Sci* 3 pp. 47–52.
- **Chevaliez S and Pawlotsky JM.(2007):** Interferon-based therapy of hepatitis C. *Adv Drug Deliv Rev*; 59:1222–1241.

- **Chevallier M, Guerret S, Chossegros P, et al.(1994):** A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies. *Hepatology*;20:349–355.
- **Cholongitas E, Senzolo M, Standish R, et al. (2006):** A systematic review of the quality of liver biopsy specimens. *Am J Clin Pathol*, 125(5):710-21.
- **Choo QL, Kuo G, Weiner AJ, et al.(1989):** "Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome". *Science* **244** (4902): 359–62.
- **Chung R, Anderson J, Volberding P, et al.(2004):** A Randomized, Controlled Trial of PEG-Interferonalfa- 2a plus Ribavirin vs Interferon-alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-co-infected Persons: Follow-up Results of ACTG A5071. Abstract 110. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA.
- **Colin C, et al.(2001):** Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. *J Viral Hepat*, 8: 87-95.
- **Comanor L, Minor J, Conjeevaram HS, et al.(2001):** Impact of chronic hepatitis B and interferon-alpha therapy on growth of children. *J Viral Hepat*;8:139–147.
- **Conjeevaram HS, Fried MW, Jeffers LJ, et al.(2006):** Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. *Gastroenterology* ; 131:470–477.

- **Conjeevaram HS, Kleiner DE, Everhart JE, et al. (2007):** Race, insulin resistance and hepatic steatosis in chronic hepatitis C. *Hepatology*; 45:80–87.
- **Crawford DH, Roberts S, Weltman M, et al.(2008):** Baseline factors associated with rapid and early virological responses in HCV genotype 1 patients treated with induction dosing of pegylated interferon: the CHARIOT study. 43rd Annual Meeting of the European Association for the Study of the Liver 2008; 23-27.
- **Crippin JS, McCashland T, Terrault N, et al.(2002):** A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. *Liver Transpl*; 8:350–355.
- **Crotty S, Cameron CE, Andino R.(2001):** RNA virus error catastrophe: direct molecular test by using ribavirin. *Proc Natl Acad Sci USA* ; 98:6895–6900.
- **Dalgard O, Bjoro K, Ring-LarsenH, et al. (2008):** Pegylated interferon alfa and ribavirin for 14 versus 24weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. *Hepatology*; 47:35–42.
- **Davis GL, Wong JB, McHutchison JG, et al. (2003):** Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology*; 38:645–652.
- **de Ledinghen V, Le Bail B, Rebouissoux L, et al.(2007):** Liver stiffness measurement in children using FibroScan: feasibility study

- and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. *J Pediatr Gastroenterol Nutr*, 45(4):443-50.
- **Degos F, Pol S, Chaix ML, et al.(2001):** The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. *Nephrol Dial Transplant*;16:1017–1023
 - **Desmet VJ, Gerber M, Hoofnagle JH, et al.(1994):** Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology*;19:1513–1520.
 - **Desmond CP, Roberts SK, Dudley F, et al. (2006):** Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. *J Viral Hepat*; 13:311–315.
 - **Di Bisceglie AM, Shiffman ML, Everson GT, et al. (2008):** Prolonged therapy of advanced chronic hepatitis C with low-dose peg-interferon. *N Engl J Med.*; 359: 2429-2441.
 - **Di Bisceglie AM. and Hoofnagle JH (2002):** Optimal therapy of hepatitis C. *Hepatology* ; 36, S121–S127.
 - **Di Marco V, Lo Iacono O, Almasio P, et al.(1997):** Long-term efficacy of alpha-interferon in beta-thalassemics with chronic hepatitis C. *Blood*;90:2207–2212.
 - **Dieterich DT (2002):** Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. *J Infect Dis*;185(suppl 2):S128–S137.

- **Distante S, Bjoro K, Hellum KB et al. (2002):** Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. *Liver*; 22:269–275.
- **Dixit NM, Layden-Almer JE, Layden TJ, et al.(2004):** Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. *Nature* ; 432:922–924.
- **El Makhzangy H, Esmat G, SaidM, et al (2009):** Response to Pegylated Interferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 4. *Journal of Medical Virology* 81:1576–1583.
- **El-Serag HB, Hampel H, Yeh C, Rabeneck L (2002):** Extrahepatic manifestations of hepatitis C among United States male veterans. *Hepatology*;36:1439-45.
- **El-Zanaty F and Way A (2009):** Egypt Demographic and Health Survey 2008. Egyptian: Ministry of Health (El-Zanaty and Associates and Macro International, Cairo), pp 431.
- **European Medicines Agency (2008):** Summary of product characteristics Pegasys ®[online].
- **Everson GT (2003):** Treatment of patients with hepatitis C on the waiting list. *Liver Transpl*;9:S90–S94.
- **Everson GT, Hoefs JC, Seeff LB, et al. (2006):** Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. *Hepatology*; 44:1675–1684.
- **Fang JWS, Lau GKK, Marousis C, et al.(1994):** Failure to detect cell surface expression of hepatitis C structural proteins using a vaccinia expression system. *Gastroenterology* 106:A890.

- **Farci P, Alter HJ, Govindarajan S, et al.(1992):** Lack of protective immunity against re-infection with hepatitis C virus. *Science* 258:135.
- **Ferenci P, (2004):** Predictors of response to therapy for chronic hepatitis C. *Semin Liver Dis.* Vol.,24:25-31
- **Ferenci P, Laferl H, Scherzer TM, et al. (2008):** Peginterferon Alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. *Gastroenterology* .
- **Ferri C, Zignego AL, Pileri SA (2002):** Cryoglobulins. *J Clin Pathol.*; 55:4-13.
- **Flisiak R, Horban A, Gallay P, et al. (2008.):** The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfectd with hepatitis C and human immunodeficiency virus. *Hepatology*;47: 817-826.
- **Foster GR, Fried MW, Hadziyannis SJ, et al.(2007):** Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40 kD) and ribavirin. *J Gastroenterol* 2007; 42(2):247-255.
- **Fracanzani AL, Conte D, Fraquelli M, et al. (2001):** Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. *Hepatology* ; 33:647–651.
- **Frank C, et al. (2000):** The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. *Lancet* 355:887–891.

- **Fraquelli M (2007):** Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. *Gut*, 56:968.
- **Fried MW, Hadziyannis SJ, Shiffman M, et al. (2008):** Rapid viral response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis c virus infection. *J Hepatol*; 48 (Suppl.2):5A.
- **Fried MW, Shiffman ML, Reddy R, et al. (2002):** Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med*; 347: 975-982.
- **Furusyo N, Hayashi J, Kanamoto-Tanaka Y, et al.(2000):** Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-year study. *Dig Dis Sci*;45: 2221–2228.
- **Gad RR, Males S, El Makhzangy H, et al. (2008):** Predictors of a sustained virological response in patients with genotype 4 chronic hepatitisC. *Liver International* (2008) The Authors. Journal compilation Blackwell Munksgaard, 1112-1117.
- **Geber WF, Lefkowitz SS, Hung CY (1975):** Effect of morphine, hydromorphone, methadone, mescaline, trypan blue, vitamin A, sodium salicylate, and caffeine on the serum interferon level in response to viral infection. *Arch Int Pharmacodyn Ther*;214:322–327.
- **Gerlach JT, Diepolder HM, Zachoval R, et al. (2003):** Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. *Gastroenterology*;125:80–88.

- **Ghany MG, Strader DB, Thomas DL, Seeff LB (2009):** Diagnosis, management, and treatment of hepatitis C: an update. *Hepatology* ;49:1335-1374.
- **Giannini E, Botta F, Borro P, Risso P, et al.(2003):** Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in liver cirrhosis. *Gut* ; 52:1200-1205
- **Glue P (1999):** The clinical pharmacology of ribavirin. *Semin Liver Dis*; 19(suppl 1):17–24.
- **Glue P, Rouzier-Panis R, Raffanel C, et al (2000):** Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. *Clin. Pharmacol. Ther* ; 68, 556–567.
- **Golub ET, Latka M, Hagan H et al. (2004):** Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck’s depression inventory. *J Urban Health* .
- **Goodman ZD (2007):** Grading and staging systems for inflammation and fibrosis in chronic liver diseases. *J Hepatol*, 47(4):598-607.
- **Goodman ZD, Becker RL, Pockros PJ, et al.(2007):** Progression of fibrosis in chronic hepatitis C: Evaluation by morphometric image analysis. *Hepatology*;45:886–894.
- **Gordon AC, Edgar JD, Finch RG (1998):** Acute exacerbation of vasculitis during interferon-alpha therapy for hepatitis C-associated cryoglobulinaemia. *J Infect*;36:229–230.

- **Gossop M, Marsden J, Stewart D, Rolfe A (2000):** Patterns of improvement after methadone treatment: 1 year follow-up results from the National Treatment Outcome Research Study. *Drug Alcohol Depend*; 60:275–286.
- **Guido M, Rugge M, Jara P, et al. (1998):** Chronic hepatitis C in children: the pathological and clinical spectrum. *Gastroenterology*;115:1525–1529.
- **Hadziyannis SJ, Sette H Jr, Morgan TR, et al. (2004):** Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med*; 140:346-355.
- **Hagan H, Snyder N, Hough E et al.(2002):** Case-reporting of acute hepatitis B and C among injection drug users. *J Urban Health*; **79**: 579–85.
- **Hahn JA (2007):** "Sex, Drugs, and Hepatitis C Virus". *J Infect Dis* **195** (11): 1556–9.
- **Hasan F, Asker H, Al Khaldi J, et al. (2004):** Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. *Am J Gastroenterol*; 99:1733–1737.
- **Hauser P (2004):** Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression. *Gastroenterol Clin North Am*; 33:S35- S50.
- **Hayasaka S, Nagaki Y, Matsumoto M, et al. (1998):** Interferon associated retinopathy. *Br J Ophthalmol*;82: 323-325.

- **Hermine O, Lefrere F, Bronowicki JP, et al.(2002):** Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. *N Engl J Med*; 347:89-94.
- **Hofer H, Osterreicher C, Jessner W, et al. (2004):** Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. *J Hepatol*; 40:1018–1022.
- **Hoofnagle J (2002):** Course and outcomes of hepatitis C. *Hepatology*,2002;36:S21-S29.
- **Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y (1993):** Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. *Gastroenterology* ;104:1116–1121.
- **Houghton M (2009):** "The long and winding road leading to the identification of the hepatitis C virus". *Journal of Hepatology* **51** (5): 939–48.
- **Hui AY, Liew CT, Go MY, et al. (2004):** Quantitative assessment of fibrosis in liver biopsies from patients with chronic hepatitis B. *Liver Int*, 24(6):611-8.
- **Hui JM, Kench J, Farrell GC, et al.(2002):** Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. *J Gastroenterol Hepatol* ; 17:873–881.
- **Hwang SJ, Luo JC, Chu CW, et al. (2001):** Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. *J Gastroenterol Hepatol*; 16:190–195. infection in patients with cryoglobulinemic neuropathy. *Ann Neurol* ;34:749–750 .

- **Ishak K, Baptista A, Bianchi L, et al. (1995):** Histological grading and staging of chronic hepatitis. *J Hepatol.*;22:696–699.
- **Jacobson IM, Brown Jr RS, Freilich B, et al (2007):** Peginterferon alfa-2b and weight-based or flat dose ribavirin in chronic hepatitis C patients: a randomized trial. *Hepatology* ; 46:971–981.
- **Jacobson KR, Murray K, Zellos A, Schwarz KB (2002):** An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. *J Pediatr Gastroenterol Nutr*;34:52–58.
- **Jensen DM, Marcellin P, Freilich B, et al.(2009):** Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. *Ann Intern Med*;150:528-540.
- **Jensen DM, Morgan TR, Marcellin P, et al. (2006):** Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ ribavirin therapy. *Hepatology*; 43:954–960.
- **Johnson RJ, Gretch DR, Yamabe H, et al.(1993):** Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. *N Engl J Med*; 328: 465-470
- **Jonas MM, Ott MJ, Nelson SP, et al.(1998):** Interferon- alpha treatment of chronic hepatitis C virus infection in children. *Pediatr Infect Dis J*;17:241–246.
- **Jorquera F, Monte MJ, Guerra J, et al. (2005):** Usefulness of combined measurement of serum bile acids and ferritin as additional prognostic markers to predict failure to reach sustained response to

- antiviral treatment in chronic hepatitis C. *J Gastroenterol Hepatol*; 20:547–554.
- **Kamal SM (2008):** 103 (5): 1283–97; quiz 1298.
 - **Kamal SM, El Kamary SS, Shardell MD, et al. (2007):** Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. *Hepatology*, Dec;46(6):1732-40.
 - **Kamal SM. (2009):** Hepatitis C genotype 4 therapy: increasing options and improving outcomes. *Liver Int*;29 Suppl 1:39-48.
 - **Kamal, S.M. and Nasser, I.A. (2008):** Hepatitis C genotype 4: what we know and what we do not know. *Hepatology*, 47(4): 1371-1383.
 - **Kamel MA, et al. (1992):** High HCV prevalence in Egyptian blood donors. *Lancet* 340: 427.
 - **Karino Y, Toyota J, Sugawara M. ,et al. (2003):** Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C. *J Gastroenterol Hepatol*; 18:404-410
 - **Karmochkine M, Carrat F, Dos Santos O,et al. (2006):** "A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection". *Journal of Viral Hepatitis* 13 (11): 775–82.
 - **Kato N (2000):** "Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation". *Microb. Comp. Genomics* 5 (3): 129–51.

- **Kau A, Vermehren J and Sarrazin C (2008):** Treatment predictors of a sustained virologic response in hepatitis B and C. *Journal of Hepatology*;49 :634–651.
- **Kessel A, Rosner I, Zuckerman E, et al. (2000):** Use of antikeratin antibodies to distinguish between rheumatoid arthritis and polyarthritis associated with hepatitis C infection. *J Rheumatol*;27:610-2.
- **Khuroo MS, Khuroo MS and Dahab ST. (2004):** Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. *Aliment Pharmacol Ther*; 20:931–938.
- **Kim R.W. (2002):** Global epidemiology and burden of hepatitis C, *Microbiol Infect* **4**, pp. 1219–1225.
- **Kleiner DE.(2005):** The liver biopsy in chronic hepatitis C: A view from the other side of the microscope. *Semin Liver Dis* ;25:52-64
- **Klumpp K, Leveque V, Le Pogam S, et al.(2006):** The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. *J Biol Chem* ;281:3793-3799.
- **Knodel RG, Ishak KG, Black WC, et al.(1981):** Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *Hepatology*;1:431–435.
- **Kobayashi S, Takeda T, Enomoto M, et al (2007):** Development of hepatocellular carcinoma in patients with chronic hepatitis C who had

- a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. *Liver Int* 2007; 27:186-191.
- **Komurian-Pradel F, et al. (2001):** Quantitation of HCV RNA using real-time PCR and fluorimetry. *J Virol Methods*, 95: 111-9.
 - **Lafeuillade A, Hittinger G, Chadapaud S (2001):** Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. *Lancet*;357:280– 281.
 - **Lalezari J, Gane E, Rodriguez-Torres M, , et al.(2008):** Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500 mg BID for 28 days. *J Hepatol*;48(suppl 2):S29.
 - **Lamarre D, Anderson PC, Bailey M, et al.(2003):** An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. *Nature* ;426:186-189.
 - **Laskus T, Wang LF, Radkowski M, et al.(2001):** *Journal of virology* 75 (5): 2059–66.
 - **Lau JY, Tam RC, Liang TJ., et al.(2002):** Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. *Hepatology* ; 35:1002–1009.
 - **Lauer G And Walker B (2001):** Hepatitis C Virus Infection. *N Engl J Med* ;345, (1), 41-52.
 - **Lecube A, Hernandez C, Simo R, et al. (2007):** Glucose abnormalities are an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. *Am J Gastroenterol*;102:2189–2195.

- **Lee S and Abdo A.,(2003):** Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon?. *Journal of Antimicrobial Chemotherapy* 2003; 51,487–491.
- **Leroy V (2007):** Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. *J Hepatol*, 46:775.
- **Lindahl K, Schvarcz R, Bruchfeld A, et al.(2004):** Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. *J Viral Hepatol* ; 11:84–87.
- **Lindsay K, Manns MP, Gordon SC et al. (2008):** Clearance of HCV at 5 year follow-up for peginterferon alfa-2b with or without ribavirin is predicted by sustained virologic response at 24 weeks post-treatment. *Gastroenterology*; 134 (Suppl. 1):772A.
- **Lindsay KL, Trepo C, Heintges T, et al.(2001):** A randomized, doubleblind trial comparing PEGylated interferon alfa-2b to interferon α -2b as initial treatment for chronic hepatitis C. *Hepatology* ; 34:395–403.
- **Lock G, Dirscherl M, Obermeier F, et al. (2006):** "Hepatitis C — contamination of toothbrushes: myth or reality?". *J. Viral Hepat.* **13** (9): 571–3.
- **Maida I, Soriano V, Barreiro P, et al.(2007):** Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfectd patients with persistently normal transaminases. *AIDS Res Hum Retroviruses*, 23(6):801-4.

- **Males S, Gad RR, Esmat G et al. (2007):** Serum alpha-fetoprotein level predicts treatment outcome in chronic hepatitis C. *Antivir Ther*; 12(5):797-803
- **Mangia A, Santoro R, Minerva N, et al. (2005):** Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. *N Engl J Med*; 352:2609–2617.
- **Manns MP, McHutchison JG, Gordon SC, et al. (2001):** Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. *Lancet*; 358: 958-965.
- **Manns, M.P.; Wedemeyer, H. and Cornberg, M. (2006):** Treating viral hepatitis C: efficacy, side effects, and complications. *Gut*, 55: 1350-1359.
- **Marcellin P, Levy S, Erlinger S (1997):** Therapy of hepatitis C: patients with normal aminotransferase levels. *HEPATOLOGY*;26(suppl 1):133S– 136S.
- **McHutchison JG, Everson GT, Gordon SC, et al.(2008):** PROVE 1: results from a phase 2 study of telaprevir with Peginterfeon alfa-2a and ribavirin in treatment-naïve subjects with hepatitis C. *J Hepatol.*; 48(suppl 2):S4.
- **McKee D. H., Young A. C., lonso-Dominguez A. A, et al. (2000):** Neurologic complications associated with hepatitis C virus infection *Neurology*; 55: 459 - 459.
- **Mehta SH, Cox A, Hoover DR, et al.(2002):** Protection against persistence of hepatitis C. *Lancet*;359: 1478–1483.

- **Meyers CM, Seeff LB, Stehman-Breen O, et al.(2003):** Hepatitis C and renal disease: an update. *Am J Kidney Dis*;42:631–657.
- **Misiani R, Bellavita P, Fenili D, et al.(1994):** Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. *N Engl J Med*;330:751–756.
- **Missiha S, Heathcote J, Arenovich T et al. (2007):** Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. *Am J Gastroenterol*; 102:2181-2188
- **Mohamed MK (2004) :** Epidemiology of HCV in Egypt. *The Afro-Arab Liver Journal*, 2004, vol 3, No2, (July), pp 41-52.
- **Mohamed MK, Abdel-Hamid M, Mikhail NN, et al.(2005):** Intrafamilial transmission of hepatitis C in Egypt. *Hepatology*; 42:683-687.
- **Moore RD (1999):** Human immunodeficiency virus infection, anemia, and survival. *Clin Infect Dis*;29:44–49.
- **Moucari R, Ripault MP, Martinot-Peignoux M et al.(2009):** Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4.*Gut*.; 58(12):1662-9.
- **Muir AJ, Bornstein JD and Killenberg PG. (2004):** Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. *N Engl J Med*; 350:2265–2271.

- **Myers RP, Fong A, Shaheen AA (2008):** Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. *Liver Int*, 28(5):705-12.
- **National Institutes of Health (NIH) (2002):** Consensus development program and the state-of-the-science conferences. Management of hepatitis C. Washington, DC: National Institutes of Health;1-46.
- **Nelson D, Rustgi V, Balan V, et al.(2005):** A phase 2 study of Albuferon in combination with ribavirin in non-responders to prior interferon therapy for chronic hepatitis C. *Hepatology*;42(suppl 1):278A.
- **Ngo Y, Munteanu M, Messous D, et al.(2006):** "A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C". *Clinical Chemistry* 52 (10): 1887–96.
- **O'Brien MJ, Keating NM, Elderiny S, et al.(2000):** An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C. *Am J Clin Pathol* ;114:712–718.
- **Op De Beeck A and Dubuisson J (2003):** "Topology of hepatitis C virus envelope glycoproteins". *Rev. Med. Virol.* 13 (4): 233–41.
- **Ortiz V, Berenguer M, Rayon JM et al. (2002):** Contribution of obesity to hepatitis C-related fibrosis progression. *Am J Gastroenterol*; 97:2408–2414.
- **Pascu M, Martus P, Hohne M, et al. (2004):** Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. *Gut*; 53:1345–1351.

- **Patel K, Norris S, Lebeck L et al (2006):** HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C. *Hepatology* ; 43(2):241–249.
 - **Pawlotsky JM (2002):** Molecular diagnosis of viral hepatitis. *Gastroenterology*, 122:1554-68.
 - **Pawlotsky JM (2004):** Treating hepatitis C in “difficult-to-treat” patients. *N Engl J Med.*;351:422-423.
 - **Pawlotsky JM, Ben Yahia , et al., (2004):**Immunologic disorders in C virus chronic active hepatitis :A prospective case control study . *Hepatology* ;19:841
 - **Pawlotsky JM, et al.(1997):** Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. *J Clin Microbiol*, 35: 1734-9.
 - **Pawlotsky JM, et al.(1998):** What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? *Hepatology*, 27: 1700-2.
 - **Perelson AS et al.(2005):** New kinetic models for the hepatitis C virus. *Hepatology* ; 42: 749–754.
 - **Perry CM and Jarvis B (2001):** Peginterferon- α -2a (40 kD), a review of its use in the management of chronic hepatitis C. *Drugs* ;61(15): 2263-2288.
 - **Petz D, Klauck S, Rohl FW, et al.(2003):** Feasibility of histological grading and staging of chronic viral hepatitis using specimens obtained by thin-needle biopsy. *Virchows Arch* , 442(3):238-44.
- Hepatology - A clinical textbook*

- **Pinzani M, Vizzutti F, Arena U, Marra F (2008):** Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. *Nat Clin Pract Gastroenterol Hepatol*, 5(2):95-106.
- **Poordad F, Shiffman ML, Sherman K, et al.(2008):** A study of telpravir with peginterferon alfa-2a and ribavirin in subjects with well-documented prior PR null response, non-response or relapse: preliminary results. *J Hepatol*;48(suppl 2):S374.
- **Powell EE, Jonsson JR and Clouston AD, (2005):** Steatosis: co-factor in other liver diseases. *Hepatology*; 42:5-13.
- **Poynard T, Colombo M, Bruix J, et al.(2009):** Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. *Gastroenterology*;136:1618-1628 e1612.
- **Poynard T, McHutchison J, Goodman Z et al. (2000):** Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. *Hepatology*; 31:211–218.
- **Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, et al.(2007):** Meta-analyses of FibroTest diagnostic value in chronic liver disease. *BMC Gastroenterol*, 7:40.
- **Poynard T, Ratziu V, McHutchison J, et al. (2003):** Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. *Hepatology*; 38: 75-85.

- **Rai R, Wilson LE, Astemborski J, et al.(2002):** Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. *HEPATOLOGY*;35:1247–1255.
- **Ray, S.C., Arthur, R.R., Carella, A., et al.(2000):** Genetic epidemiology of hepatitis C virus throughout Egypt. *J. Infect. Dis.*, 182:698-707.
- **Reddy KR, David RN, Zeuzem S, et al.(2009):** Ribavirin: Current role in the optimal clinical management of chronic hepatitis C. *J Hepatol* ; 50:402–411.
- **Reddy KR, Fried MW, Dixon R, et al.(2002):** Interferon alfa-2b and ribavirin vs placebo as early treatment in patients transplanted for hepatitis C end-stage liver disease: results of a multi-center, randomized trial. *Gastroenterology*;122:199.
- **Reddy KR, Wright TL, Pockros PJ, et al.(2001):** Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. *HEPATOLOGY*;33:433–438.
- **Rigopoulou EI, Abbott WG, Williams R, et al.(2007):** Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus. *Antiviral Res* ; 5:36–42.
- **Romero-Gomez M, Del Mar Vilorio M, Andrade RJ, et al. (2005):** Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. *Gastroenterology*; 128: 636-641.

- **Rossignol J-F, Elfert A, Keefe EB (2008):** Evaluation of a 4 week lead-in phase with nitazoxanide prior to nitazoxanide + peginterferon in treating chronic hepatitis C. *J Hepatol*;48(suppl 2):S312.
- **Roulot D, Bourcier V, Grando V, et al (2007):** Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. *J Viral Hepat* 2007; 14: 460–7.
- **Roulot D, Czernichow S, Le Clesiau H, et al. (2008):** Liver stiffness values in apparently healthy subjects: Influence of gender and metabolic syndrome. *J Hepatol*.
- **Ryan KJ and Ray CG (2004):** Sherris Medical Microbiology (4th ed.). McGraw Hill. pp. 551–2.
- **Sagir A, Erhardt A, Schmitt M, Haussinger D (2008):** Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. *Hepatology*, 47(2):592-5.
- **Sakr MA, Esmat G, Hamid WA, et al.(2006):** Effect of body mass index, diabetes mellitus and hepatic steatosis on response to peg-interferon therapy in chronic HCV patients genotype 4. *Ain shams faculty of medicine* 2006; 144- 153.
- **Salama MM, Abou Gabal AK, Tharwa ES, et al.(2010):** Gamma glutamyl traspeptidase and alphafetoprotein: Are they predictors of treatment response in chronic hepatitis C patients? *National liver institute, Menoufiya university* 2010; 79-85.
- **Salama MM, Gameel KA, El Shereafy MS et al. (2007):** Assessment of steatosis in chronic hepatis C patients responders & nonresponders

- to combined pegylated interferon and ribavarin therapy. National liver institute, Menoufiya university 2007; 6: 80-90; 3: 40-43
- **Saleh DA, et al.(2008):** Incidence and risk factors for hepatitis C infection in a cohort of women in rural Egypt. *Trans R Soc Trop Med Hyg* 102:921–928.
 - **Salmeron J, Casado J, Rueda PM, et al. (2008):** Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin. *J Clin Virol*; 41:264–269.
 - **Samuel D, Bizollon T, Feray C, et al.(2003):** Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. *Gastroenterology*;124:642–650.
 - **Sanchez-Tapias JM, Diago M, Escartin P, et al. (2006):** Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. *Gastroenterology*; 131:451–460.
 - **Sandrin L, Catheline S, Tanter M, et al.(1999):** Time-resolved pulsed elastography with ultrafast ultrasonic imaging. *Ultrason Imaging*;21(4):259-72.
 - **Schaefer M, Schmidt F, Folwaczny C, et al.(2003):** Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. *HEPATOLOGY*;37:443–451.
 - **Schering Corporation (2006):** PEG-Intron (Peginterferon alfa-2b) powder for injection: US prescribing information 2006.

- **Schirmacher P, Fleig WE, Dienes HP (2004):** (Biopsy diagnosis of chronic hepatitis). *Z Gastroenterol*; 42(2):175- 85.
- **Seeff LB., (2005):** Natural history of hepatitis C. *Hepatology. Rev.* Vol.,2:88-96
- **Shaheen AA and Myers RP (2007):** Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. *Hepatology*, 46(3):912-21.
- **Shaheen AA, Wan AF, Myers RP (2007):** FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. *Am J Gastroenterol*, 102(11):2589-600.
- **Shakil AO, Conry-Cantilena C, Alter HJ, et al.(1995):** Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. *Ann Intern Med*;123:330– 337.
- **Shakil AO, McGuire B, Crippin J, et al.(2002):** A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. *HEPATOLOGY*;36:1253–1258.
- **Sharaf Eldin N, Ismail S, Mansour H, et al. (2008) :** Symptomatic Acute Hepatitis C in Egypt: Diagnosis, Spontaneous Viral Clearance, and Delayed Treatment with 12 Weeks of Pegylated Interferon Alfa-2a. *PLoS ONE* 3(12): e4085. doi:10.1371/journal.pone.0004085 .
- **Shiffman ML, SuterF, Bacon BR et al (2007):** Peg interferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. *N Engl J Med* ; 357:124–134.
- **Shobokshi OA, Serebour FE, Skakni L, et al.(2003) :** Pegylated interferon alfa-2a (40kDa) as a monotherapy or in combination with

ribavirin significantly improves end of treatment response rate in hepatitis C virus genotype 4 chronic active hepatitis patients.

- **Siddique I, El-Naga HA, Madda JP, et al.(2003):** Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. *Scand J Gastroenterol*, 38(4):427-32.
- **Silva IS, Ferraz ML, Perez RM, et al. (2004):** Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. *J Gastroenterol Hepatol*; 19:314–318.
- **Silva L.K., Silva M.B., Rodart I.F., et al.(2006):** Prevalence of hepatitis C virus (HCV) infection and HCV genotypes of hemodialysis patients in Salvador, Northeastern Brazil, *Braz J Med Biol Res* **39**, pp. 595–602.
- **Simmonds P, Bukh J, Combet C, et al.(2005):** "Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes". *Hepatology* **42** (4): 962–73.
- **Skripnova S, Trainer TD, Krawitt EL, Blaszyk H (2007):** Variability of grade and stage in simultaneous paired liver biopsies in patients with hepatitis C. *J Clin Pathol*, 60(3):321-4.
- **Sporea I, Danila M, Sirli R, et al.(2006):** Comparative Study Concerning the Efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in Patients with Chronic Viral C Hepatitis. *Gastrointestin Liver Dis* 2006;15(2):125-130.
- **Standish RA, Cholongitas E, Dhillon A, et al.(2006):** An appraisal of the histopathological assessment of liver fibrosis. *Gut*, 55(4):569-78.

- **Stefan Mauss ,Thomas Berg ,Juergen Rockstroh , et al.(2009) :** Hepatitis C - Epidemiology, transmission and natural history. *Hepatology* 3: 37-48.
- **Stehman-Breen C, Alpers CE, Couser WG, et al.(1995):** Hepatitis C virus associated membranous glomerulonephritis. *Clin Nephrol*; 44:141-7 .
- **Strader D.B., Wright T., Thomas D.L., Seeff L.B. (2004):** Diagnosis, management, and treatment of hepatitis C. American Association for the Study of Liver Diseases Practice Guideline. *Hepatology* 2004; 39:1147-1171.
- **Sulkowski M, Shiffman ML, Afdhal NH et al.(2008):** Treatment-related anemia but not epoetin use (EPO) is associated with higher SVR rates among persons treated with peginterferon (PEG)/ribavirin (RBV): Results from the IDEAL Study. 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2008). San Francisco; Abstract 1851.
- **Sulkowski M, Wasserman R, Brooks L, et al.(2004):** Changes in hemoglobin during interferon alfa 2b plus ribavirin combination therapy for hepatitis C virus infection. *J Viral Hepat*.
- **Sulkowski MS, Thomas DL, Chaisson RE, Moore RD (2000):** Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. *JAMA*;283:74–80.
- **Susser S, Welker MW, Zettler M, et al.(2008):** Clonal analysis of mutations selected in the HCV NS3 protease domain of genotype 1 non-responders treated with bocepravir (SCH503034). *J Hepatol*; 48(suppl 2):S29.

- **Suzuki T, Yonemura K, Miyaji T, et al.(2001):** Progressive renal failure and blindness due to retinal hemorrhage after interferon therapy for hepatitis C virus-associated membranoproliferative glomerulonephritis. *Intern Med*;40:708–712.
- **Talaat M et al.(2006):** Evolution of infection control in Egypt: Achievements and challenges. *Am J Infect Control* 34:193–200.
- **Tanaka ,Y.; Agha ,S.; Saady , N .; et al (2004) :** Exponential spread of hepatitis C virus genotype 4 a in Egypt. *Journal of molecular science* .
- **Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. (2004):** Peginterferon alfa- 2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. *N Engl J Med*; 351:438-450.
- **Vescio MF, Longo B, Babudieri S, et al.(2008):** "Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis". *Journal of Epidemiology and Community Health* **62** (4): 305–13.
- **Villano SA, Vlahov D, Nelson KE, et al.(1999):** Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. *HEPATOLOGY*;29:908–914.
- **Vo NV, Young KC, Lai MM (2003):** Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. *Biochemistry* ; 42:10462–10471.
- **Von Wagner M, Huber M, Berg T (2005):** Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. *Gastroenterology*; 129(2):522-7.

- **Waked IA, Rewisha EA, Abd ELwahed AS, et al.(2009):** Early, end of treatment and sustained virological response of interferon plus ribavarin, does it differ in patients with chronic hepatitis c with normal versus elevated trasaminases? National liver institute, Menoufiya university 2009; 87-93
- **Wasley A and Alter M (2000):** Epidemiology of hepatitis C: geographic differences and temporal trends, Semin Liver Dis **20**, pp. 1–16.
- **Wilson SE, Lee WM, Murakami C, et al.(1994):** Mooren type hepatitis C virus associated corneal ulceration. Ophthalmology, 101: 736-745.
- **Yao x, Dao-Zhen X, Zhi-Meng L, et al. (2005):** predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open and multi-center controlled trial. Hepatobiliary pancreat Dis Int, 2005; 4 :213-219.
- **Yoneda M (2007):** Transient elastography in patients with nonalcoholic fatty liver disease (NAFLD). Gut, 56:1330.
- **Zeuzem S (2008):** Interferon-based therapy for chronic hepatitis C: current and future perspectives. nature clinical practice J Gastroenterol Hepatol 2008; 5(11):610-622.
- **Zeuzem S, Buti M, Ferenci P (2006):** Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol; 44(1): 97-103.

References

- **Zeuzem S, Feinman SV, Rasenack J, et al.(2000):** Peginterferon alfa-2a in patients with chronic hepatitis C. *N Engl J Med*;343:1666–1672.
- **Zhu B, Zhang P, Wang XH et al. (2006):** A virological response study of serum leptin level and insulin resistance on the antiviral effect in patients with chronic hepatitis C ; 14(12):887-9.
- **Zuckerman E, Keren D, Slobodin G, et al.(2000):** Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. *J Rheumatol*;27:2172–2178.